Edgewise Therapeutics, Inc. - EWTX

Ownership (Schedule 13D / 13G) · latest 50 filings · Back to all files
Visible: 0
Filed Form Reporting person Percent Shares SEC
Feb 17, 2026 SCHEDULE 13G/A Paradigm BioCapital Advisors LP 6.2% 6,541,210 View
Feb 17, 2026 SCHEDULE 13G/A Paradigm BioCapital Advisors GP LLC 6.2% 6,541,210 View
Feb 17, 2026 SCHEDULE 13G/A Senai Asefaw, M.D. 6.2% 6,541,210 View
Feb 17, 2026 SCHEDULE 13G/A Paradigm BioCapital International Fund Ltd. 5.5% 5,778,924 View
Nov 14, 2025 SCHEDULE 13G/A RA Capital Management, L.P. 9.9% 10,428,437 View
Nov 14, 2025 SCHEDULE 13G/A Peter Kolchinsky 9.9% 10,428,437 View
Nov 14, 2025 SCHEDULE 13G/A Rajeev Shah 9.9% 10,428,437 View
Nov 14, 2025 SCHEDULE 13G/A RA Capital Healthcare Fund, L.P. 9.9% 10,428,437 View
Nov 14, 2025 SCHEDULE 13G/A JANUS HENDERSON GROUP PLC 4.7% 4,979,331 View
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G. Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F). Amendments (/A) can repeat the same holder over time, so rows should not be summed. Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.